Payment overview · 2025
General Payments
$657.34
31 reported records · 12 companies
Healthcare provider profile · identity verified
Shannon Davis Wise, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NAPLES, FL · NPI 1891088910
Verified facts
What the public records show
CMS Open Payments records show Shannon Davis Wise, MD received $657.34 in general payments during 2025 across 31 reported records.
Novo Nordisk Inc accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Prolia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $121.90 | 18.5% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $108.51 | 16.5% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $96.63 | 14.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $83.25 | 12.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $66.93 | 10.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.54 | 6.3% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $31.48 | 4.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.47 | 4.8% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$25.91 | 3.9% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $19.95 | 3.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.98 | 2.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.79 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $657.34 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $83.25 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $83.25 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $69.45 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $55.95 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $52.56 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $52.56 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.75 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.32 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $41.54 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $41.54 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $31.48 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $31.47 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.18 | 1 | 2025 |
Source payment records
|
|||||
| PROPEL Normalized: propel |
Device | Medtronic, Inc. | $25.91 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 78 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
76 | 24 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
21 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
116 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 623 | 178 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 489 | 155 |
| Amlodipine Besylate | Amlodipine Besylate | 450 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 377 | 107 |
| Losartan Potassium | Losartan Potassium | 365 | 108 |
| Lisinopril | Lisinopril | 339 | 105 |
| Tamsulosin Hcl | Tamsulosin Hcl | 251 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 243 | 74 |
| Omeprazole | Omeprazole | 231 | 70 |
| Metformin Hcl | Metformin Hcl | 220 | 69 |
| Simvastatin | Simvastatin | 203 | 59 |
| Gabapentin | Gabapentin | 167 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 147 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 142 | 43 |
| Allopurinol | Allopurinol | 128 | 35 |
| Sertraline Hcl | Sertraline Hcl | 126 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 37 |
| Alprazolam | Alprazolam | 116 | 45 |
| Ozempic | Semaglutide | 116 | 22 |
| Methylprednisolone | Methylprednisolone | 109 | 88 |
| Furosemide | Furosemide | 107 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 101 | 32 |
| Trazodone Hcl | Trazodone Hcl | 94 | 34 |
| Meloxicam | Meloxicam | 91 | 27 |
| Bupropion Xl | Bupropion Hcl | 83 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 30 |
| Eliquis | Apixaban | 78 | 25 |
| Synthroid | Levothyroxine Sodium | 76 | 24 |
| Carvedilol | Carvedilol | 72 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 27 |
| Jardiance | Empagliflozin | 68 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 41 |
| Alendronate Sodium | Alendronate Sodium | 65 | 23 |
| Famotidine | Famotidine | 63 | 23 |
| Ezetimibe | Ezetimibe | 61 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 27 |
| Montelukast Sodium | Montelukast Sodium | 60 | 20 |
| Spironolactone | Spironolactone | 60 | 19 |
| Cephalexin | Cephalexin | 53 | 39 |
| Ipratropium Bromide | Ipratropium Bromide | 53 | 26 |
| Finasteride | Finasteride | 51 | 15 |
| Metformin Hcl Er | Metformin Hcl | 51 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 41 |
| Estradiol | Estradiol | 49 | 19 |
| Valsartan | Valsartan | 48 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 16 |
| Potassium Chloride | Potassium Chloride | 46 | 18 |
| Atenolol | Atenolol | 45 | 11 |
| Celecoxib | Celecoxib | 45 | 16 |
| Tramadol Hcl | Tramadol Hcl | 44 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 12 |
| Glimepiride | Glimepiride | 42 | 13 |
| Prednisone | Prednisone | 42 | 21 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 38 | 17 |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Irbesartan | Irbesartan | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 11 |
| Xarelto | Rivaroxaban | 35 | 12 |
| Azithromycin | Azithromycin | 33 | 29 |
| Glipizide | Glipizide | 33 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 12 |
| Ramipril | Ramipril | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 21 |
| Colchicine | Colchicine | 31 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 14 |
| Lorazepam | Lorazepam | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | 15 |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 18 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 15 |
| Prolia | Denosumab | 21 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 13 |
| Glipizide Er | Glipizide | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Torsemide | Torsemide | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $657.34 · 31 records | Novo Nordisk Inc | AREXVY, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, EVENITY, Extended Holter, GARDASIL 9, INSPIRE, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, PROPEL, QULIPTA, REPATHA, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error